Drugs / ICP-322
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07236099 | Nov 2025 → Mar 2027 expected | prurigo nodularis | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07236099 ↗ |